Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by Polaris Capital Management LLC

Polaris Capital Management LLC increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 14.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 35,100 shares of the company’s stock after purchasing an additional 4,300 shares during the quarter. Polaris Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $806,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. GAMMA Investing LLC raised its stake in Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after acquiring an additional 424 shares in the last quarter. Signaturefd LLC raised its stake in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock worth $25,000 after acquiring an additional 520 shares in the last quarter. Hohimer Wealth Management LLC raised its stake in Amphastar Pharmaceuticals by 6.9% during the 1st quarter. Hohimer Wealth Management LLC now owns 8,005 shares of the company’s stock worth $232,000 after acquiring an additional 520 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Amphastar Pharmaceuticals by 13.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,783 shares of the company’s stock worth $139,000 after acquiring an additional 580 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Amphastar Pharmaceuticals by 2.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock worth $652,000 after acquiring an additional 613 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Up 0.9%

AMPH stock opened at $26.75 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $53.96. The company has a market cap of $1.24 billion, a P/E ratio of 10.02 and a beta of 0.75. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The company’s 50-day moving average price is $27.30 and its 200 day moving average price is $25.54.

Wall Street Analyst Weigh In

AMPH has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Saturday, September 27th. Needham & Company LLC upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $36.00 price objective on the stock in a research note on Tuesday, August 12th. Bank of America lifted their price objective on shares of Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 26th. Finally, Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.